Search

This case report discusses a female patient with axial spondyloarthritis (AS) who developed inflammatory bowel disease (IBD) after being treated with secukinumab (SEC), an interleukin-17 inhibitor. The patient had a family history of AS and psoriasis, and her symptoms worsened after starting SEC treatment. She experienced upper abdominal pain, nausea, vomiting, and gastrointestinal bleeding. The report highlights the association between SEC and the exacerbation of gastrointestinal symptoms leading to IBD. It also mentions the low incidence rate of IBD in patients treated with SEC and the lack of reports on neurological damage associated with SEC use. [Extracted from the article]

Aims: Lymphoepithelioma‐like carcinomas (LELCs) are uncommon epithelial cancers characteristically showing two distinct components consisting of malignant epithelial cells and prominent dense lymphoid infiltrate. Hepatic LELCs consist of two types, the lymphoepithelioma‐like hepatocellular carcinoma and lymphoepithelioma‐like cholangiocarcinoma (LEL‐CCA), with the latter being strongly associated with Epstein–Barr virus (EBV). Methods and results: We present a series of three cases of intrahepatic biliary EBV‐associated LEL tumours in which the biliary epithelial component showed a distinctly benign appearance, instead of the usual malignant epithelial features of a typical CCA or EBV‐associated LEL‐CCA. In the lesions, the biliary epithelium showed interconnecting glands or cords of cells. All had a very low proliferation (Ki‐67) index. Immunohistochemistry for IDH1 and TP53 performed on two cases was negative and molecular tests for EGFR and KRAS gene mutations performed on one were negative. Prognosis was very good in all three cases, with patients alive with no evidence of disease 24–62 months after surgery. Intriguingly, all three cases had co‐infection of HBV and EBV. These cases are also discussed in the context of the 63 cases of LEL‐CCA available in the literature, with a focus on epidemiology, clinicopathological features and potential research interests. Conclusions: Based on the distinct clinicopathological features and unique survival benefits, we believe these tumours represent the benign end of the spectrum of EBV‐associated lymphoepithelial biliary carcinomas. Whether these tumours require a revision of the current nomenclature to 'lymphoepithelioma‐like neoplasm of the biliary tract with probable low malignant potential' will require more detailed analysis with larger case‐series. [ABSTRACT FROM AUTHOR]

Although selective COX-2 inhibitors have cancer-preventive effects and induce apoptosis, the mechanisms underlying these effects are not fully understood. This study investigated the effects of nimesulide, a selective COX-2 inhibitor, on apoptosis and on the JAK/STAT signaling pathway in Eca-109 human esophageal squamous carcinoma cells. The effects and mechanisms of nimesulide on Eca-109 cell growth were studied in culture and in nude mice with Eca-109 xenografts. Cells were cultured with or without nimesulide and/or the JAK2 inhibitor AG490. Cell proliferation was evaluated using the MTT assay, and apoptosis was investigated. COX-2 mRNA expression was measured using reverse transcription polymerase chain reaction, and protein expression was detected by Western blot analysis, immunohistochemistry, and flow cytometry. Nimesulide significantly inhibited Eca-109 cell viability in vitro in a dose- and time-dependent manner (P<0.05). Nimesulide also induced apoptosis, which was accompanied by a significant decrease in the expression of COX-2 and survivin and an increase in caspase-3 expression. Nimesulide downregulated the phosphorylation levels of JAK2 and STAT3, and JAK2 inhibition by AG490 significantly augmented both nimesulide-induced apoptosis and the downregulation of COX-2 and survivin (P<0.05). In vivo, nimesulide inhibited the growth of Eca-109 tumors and the expression of p-JAK2 and p-STAT3. Thus, nimesulide downregulates COX-2 and survivin expression and upregulates caspase-3 expression in Eca-109 cells, by inactivating the JAK2/STAT3 pathway. These effects may mediate nimesulide-induced apoptosis and growth inhibition in Eca-109 cells in vitro and in vivo., (Copyright © 2015 Elsevier GmbH. All rights reserved.)

Objective: To study the clinical significance of abnormal protein bands (APB) in multiple myeloma (MM) patients treated with bortezomib-based induction regimen and autologous stem cell transplantation (ASCT)., Methods: Sixty-eight MM patients submitted to bortezomib-based induction therapy and ASCT from January 2007 to July 2012 were retrospectively studied. Monoclonal protein was detected by immunofixation electrophoresis (IFE)., Results: Of all 68 patients, 33 (48.5%) patients had APB. At the first emergence of an APB, two patients with light chain type achieved CR and before transplantation, and thirty-one patients were after transplantation with median time of 104 (ranged 33-404) days. The median duration of APB appearance was 105 (ranged 35-801) days. Patients who developed APB compared with those without APB, had a significantly higher CR plus very good partial response (VGPR) rates (100.0% vs 85.7%%, P=0.017) and CR rates (87.9% vs 62.9%) (P=0.03). There were no significant differences in gender, age, HGB, ALB, β2-microglobulin, M protein type, Durie-Salmon and ISS stages, the case number of first line or second line treatment, induction courses of bortezomib-based regimen, and the mode of ASCT. With a median follow-up of 33.4 (ranged 7.0-71.7) months, patients with APB tended to have a longer overall survival (OS) versus non-APB patients, although no significant difference obtained (P＞0.05). Among APB patients, OS was longer in patients whose appearance of APB occurred ＜6 months after transplantation than those ≥ 6 months, but the significant difference was not obtained yet (P＞0.05)., Conclusions: Patients who developed APB had a significantly better response to bortezomib-based induction regimen followed ASCT. APB emergence has a good prognostic significance.

Objective: To study the humoral immunity reconstitution and its relationship with infection in patients with multiple myeloma (MM) after undergoing autologous hematopoietic stem cell transplantation (auto-HSCT)., Methods: Forty-two MM patients undergoing auto-HSCT were included in this study. Peripheral blood were obtained for immunoglobulin detection, including IgG, IgA and IgM before transplantation and 1, 3, 6, 12, 18 and 24 months after transplantation. The time, type, pathogen of infection between 1 and 24 month after transplantation were analyzed., Results: The level of IgA at 6 month [(0.75±0.59) g/L] after auto-HSCT was lower than that of pre-auto-HSCT [(1.04±0.70) g/L], and reached the level of pre-auto-HSCT at 9 months [(0.99±0.52) g/L] after auto-HSCT. The level of IgM reached the level of pre-auto-HSCT [(0.45±0.26) g/L] at 3 months after auto-ASCT [(0.50±0.26) g/L]. The level of IgG reached the level of pre-auto-HSCT [(9.80±2.98) g/L] at 1 month after auto-HSCT [(11.09±2.69) g/L], and higher than that of pre-auto-HSCT at 9 months after auto-HSCT [(12.07±3.57) g/L]. The level of IgG with IgG-type MM was higher than that of patients with light-chain type and IgD-type MM at 6, 9 and 12 months after auto-HSCT. The IgA level of patients who obtained complete remission (CR) is much higher than that of patients who obtained nCR in IgG-type patients. The incidence of infection in 6 month after auto-HSCT was higher than that of (6-12) month and >12 month after auto-HSCT. The incidence of infection was strongly negative correlated with IgA (r =-0.943, P=0.005) and IgG (r=-0.943, P=0.005) level. The frequency of viral infection was also negatively correlated with IgA and IgG., Conclusion: The reconstitution time of IgG, IgA and IgM was different in MM patients after auto-HSCT. IgG recovered first, then IgM, and IgM the last. The incidence of infection was negatively correlated with IgA and IgG. With the recovery of IgG and IgA, the incidence of infection was decreased accordingly.

Background: Whether the sequential treatment with bortezomib plus dexamethasone (BD) followed by autologous hematopoietic stem cell transplantation (ASCT) could extend the overall survival period in multiple myeloma patients is still not clear. Few large case studies about this therapeutics in multiple myeloma were reported in China. Our purpose was to assess the efficacy and adverse effects of sequential treatment with BD chemotherapy and ASCT in patients with multiple myeloma., Methods: Fifty-three patients with newly diagnosed or relapsed/refractory multiple myeloma received BD as induction therapy before ASCT. Stem-cell mobilization was undertaken with cyclophosphamide 3 - 5 g/m(2) plus granulocyte colony-stimulating factor 300 µg/d. Target yield was 2.0×10(6) CD34(+) cells/kg. Conditioning for ASCT consisted of melphalan 200 mg/m(2). Thalidomide and/or a-interferon was used as post-transplantation maintenance treatment., Results: The BD chemotherapy before transplantation was effective in 86.7% of the 53 patients, including 22.6% with complete remission (CR), 39.6% with near complete remission (nCR), and 24.5% with partial remission (PR). The best effect was achieved after two treatment courses. Most bortezomib-related adverse effects were classes 1 - 2. All patients were successfully mobilized after BD for autologous peripheral blood stem cell transplantation. The ASCT was effective in 96.3% of patients, including 49.1% with CR, 32.1% with nCR, and 15.1% with PR. The CR rate was significantly increased (49.1% vs. 22.6%, P < 0.05) by sequential ASCT. Within 27 (range, 6 - 53) months of follow-up, the efficacy of ASCT was maintained in 29 patients and further enhanced by post-transplantation maintenance treatment in four patients. Eleven patients died after transplantation. Among the patients undergoing BD/ASCT treatment, overall survival (OS) was significantly better in newly diagnosed patients in comparison to relapsed/refractory patients (P = 0.046)., Conclusions: BD chemotherapy can be used as an induction therapy prior to ASCT in patients with multiple myeloma. Its rate of effectiveness is high and it alleviates symptoms quickly without affecting peripheral blood stem cell collection. The majority of adverse effects are mild (tolerable). Sequential BD with ASCT is the preferred option for transplant patients. First-line ASCT could prolong survival of newly diagnosed patients rather than delayed ASCT.

Objective: To investigate the efficacy and safety of bortezomib-based induction regimen followed by autologous hematopoietic stem cell transplantation (ASCT) in patients with multiple myeloma (MM)., Methods: A retrospective analysis was performed upon clinical data of 62 MM patients who received bortezomib-based induction regimen followed by ASCT from June 2006 to June 2011. All patients were followed up to September 30, 2011., Results: Overall response rate [complete remission (CR) + near complete remission (nCR) + partial remission (PR)], ≥ nCR rate (CR/nCR) and CR rate of post-induction with bortezomib-based regimen were 88.7%, 66.1% and 24.2%, respectively. After ASCT, CR rate and CR/nCR rate were increased to 50.0% and 82.3%, respectively, with significant differences (P = 0.003 and P = 0.032). The median time of neutrophil and platelet engraftment was 12.0 (9 - 43) days and 13.5 (0 - 120) days, respectively. Significances were found in neutrophil and platelet engraftment between MM patients with and without prior exposure to alkylating agents. Furthermore, engraftment of neutrophil and platelet in patients receiving peripheral blood stem cell transplantation were faster than those receiving bone marrow transplantation. No unexpected side effects occurred. The median time of follow-up was 26.5 (7-61) months. The median overall survival (OS) was not reached and the median progression-free survival (PFS) was 30 months. There were significant differences in OS and PFS between patients obtaining CR/nCR and those with ≤ PR before ASCT., Conclusions: Bortezomib-based induction regimen can improve the efficacy of ASCT in MM patients. The side effects are tolerant. Higher response quality before ASCT can translate to high rates of OS and PFS following high-dose therapy and stem cell transplantation.

Objective: To explore the efficacies and toxicities in multiple myeloma (MM) patients on the maintenance therapies of thalidomide and interferon-α so as to seek the optimal chemotherapeutic regimen., Methods: A retrospective analysis was conducted for 57 MM patients on the maintenance therapies of thalidomide and interferon-α after introduction and consolidation. And 56 MM patients without maintenance therapy were enrolled as the control group., Results: The values of progression-free survival (PFS) and overall survival (OS) were significantly longer in the maintenance group and this translated into an improved estimated 3-year PFS of 75.4% (71.8%, 83.3%) versus 23.2% in the control group (P < 0.01). The estimated 4-year OS was higher in the maintenance group [89.5% (89.7%, 88.9%) vs 33.9%, P < 0.01]. No statistically significant differences existed among different maintenance groups in terms of PFS and OS. The administration of maintenance therapy extended both PFS and OS for MM patients of various M-proteins (P < 0.05). However, in the thalidomide group, PFS and OS were extended only in MM of immunoglobulin G (IgG) and immunoglobulin A (IgA) but not in light-chain patients. Furthermore, the MM patients of Durie-Salmon (DS) stages II and III and international staging system (ISS) stages II and III extended PFS and OS through maintenance (P < 0.05). While in those of ISS stage I, the differences were insignificant in terms of PFS and OS between two groups. The results were similar between the thalidomide and control groups. The patients achieving a partial remission (PR) or higher response level benefited from the maintenance therapy in terms of PFS and OS (P < 0.05). In the thalidomide group, the patients with below PR prolonged OS (P = 0.031) but did not achieve a longer PFS (P = 0.091). Both PFS and OS were extended through maintenance therapy after either stem cell transplantation or consolidation chemotherapies (P < 0.05). There was no significant difference in terms of PFS and OS between MM patients without maintenance therapy after transplantation and those without transplantation. The adverse effects of thalidomide, milder than those of interferon-α, could be tolerated in most patients. The incidence and severity of adverse effects showed no significant difference between the combination maintenance and single agent therapies., Conclusion: The maintenance therapies of thalidomide and interferon-α could improve the profiles of PFS and OS in MM patients. And there was no significant difference between them in terms of PFS and OS. However, the maintenance therapy of thalidomide is a better option due to its convenient application, milder adverse effects, reasonable cost and better efficacies in MM patients not achieving PR or receiving induction therapy without bortezomib or without transplantation.

Objective: To evaluate the expression of N-cadherin and β-catenin protein and their relationship with clinicopathological characteristics of osteosarcoma., Methods: The expressions of N-cadherin and β-catenin at protein level were detected by immunohistochemical staining in 54 cases of osteosarcoma, 11 cases of osteoid osteoma, 7 cases of osteoblastoma and 8 cases of newly formed bone in nonmalignant bone diseases. The relationship between the two indexes and clinicopathological characteristics of osteosarcoma was analyzed., Results: In newly formed bone, osteoblastoma, osteoid osteoma and osteosarcoma, the positive expression rate of N-cadherin protein was 75.0%, 71.4%, 63.6% and 35.2%, respectively. The positive expression rate of N-cadherin protein in osteosarcoma was significantly lower than that in osteoid osteoma, osteoblastoma and newly formed bone in nonmalignant bone diseases (P = 0.035). The positive expression rate of N-cadherin protein in osteosarcoma cases with pulmonary metastasis was lower than that in cases without (21.7% vs. 56.3%, P = 0.027). The positive expression rate of N-cadherin protein in osteosarcoma cases died in two years was lower than that in cases lived for more than two years (18.2% vs. 50.0%, P = 0.024). In newly formed bone, osteoblastoma, osteoid osteoma and osteosarcoma, the aberrant expression rate of β-catenin protein was 12.5%, 28.6%, 27.3% and 66.7%, respectively. The aberrant expression rate of β-catenin protein in osteosarcoma was significantly higher than that in osteoid osteoma, osteoblastoma and newly formed bone (P = 0.002). Aberrant expression rate of β-catenin in osteosarcoma cases with pulmonary metastasis was higher than that without (82.6% vs. 43.8%, P = 0.011). An inverse correlation was found between the aberrant expression of β-catenin and N-cadherin expression in osteosarcoma(r = -0.302, P = 0.027)., Conclusion: The positive expression rate of N-cadherin is decreased in osteosarcoma while aberrant expression rate of β-catenin increased. The expression of N-cadherin protein is closely correlated with the metastasis and prognosis of osteosarcoma, but the expression of β-catenin protein is merely correlated with the metastasis of osteosarcoma.

Objective: To compare the pathologic changes, the recurrence rate and the ocular surface damage after 4 different types of pterygium surgical procedures., Methods: It is a prospective study. From Mar. 2006 to Mar. 2008, 84 patients (93 eyes) from Shi Jia-zhuang Center Hospital were selected and separated into 4 groups as follows, simple excision group, 24 patients (27 eyes); excision with conjunctival allograft group, 21 patients (22 eyes) excision with autologous limbus stem cell transplantation group, 18 patients (20 eyes) and excision with mitomycin (MMC) group, 21 patients (24 eyes). Slit lamp microscope examination and impression cytology were performed 1 day before the surgery and repeated 30 and 90 days after the surgery. Multivariate analysis of variance was used to analyze these data with statistical software SPSS 11.0. P value less than 0.05 was considered statistically significant., Results: Before the surgery, slight conjunctival epithelium keratinization, mild acantholysis and decrease in goblet cells density were identified in all patients (248.8 +/- 97.3, 256.2 +/- 75.1, 236.1 +/- 87.9, 245.1 +/- 81.0; F = 0.029, P = 0.993). All of these changes decreased 1 month after the surgery. MMC group showed more goblet cells than the other 3 groups, but the difference was not statistically significant (F = 0.747, P = 0.554). Three months after the surgery, all of these changes in MMC group (112.1 +/- 56.8) were significantly more severe than those in other 3 groups (309.6 +/- 77.0, 314.1 +/- 68.9, 317.4 +/- 73.2; F = 6.337, P = 0.017) and no difference could be detected between these 3 groups. There were 5 recurrences in simple excision group, 3 recurrences in MMC group, 1 recurrence in stem cell transplantation group and none in conjunctival allograft group., Conclusions: There are fewer recurrent cases in conjunctival allograft group and stem cell transplantation group than the others. Severe ocular surface damage is present in MMC group.

Objective: To study the clinical features and risk factors of invasive fungal infection (IFI) in multiple myeloma (MM)., Methods: Three hundred and fifty-seven cases of MM were retrospectively analyzed for IFI, clinical features, complicating diseases, treatment of fungus and side effect of anti-fungal drugs., Results: Forty-four cases (12.3%) of IFI were diagnosed. Three of them were diagnosed definitely, 8 clinically and 33 probably. Ten cases incurred IFI in the induction therapy, 4 in platform, 27 in progress and 3 in the treatment with autologous stem cell transplantation. The lung was the commonest site of infection (50.0%). The total effective rates of amphotericin B liposome, voriconazole, itraconazole, caspofungin and fluconazol were 83.3%, 75.0%, 78.9%, 75.0% and 57.1% respectively (P = 0.493). In a multivariate analysis, independent factors significantly associated with IFI were diabetes (P = 0.035, OR 2.527, 95%CI 1.005 - 6.052), dialysis (P = 0.022, OR 2.768, 95%CI 1.161 - 6.600), persistent agranulocytosis (P = 0.019, OR 3.215, 95%CI 1.200 - 7.407), broad-spectrum antibiotic therapy (P = 0.009, OR 3.350, 95%CI 1.353 - 8.295) and fludarabine treatment (P = 0.001, OR 4.669, 95%CI 1.813 - 12.023)., Conclusions: Patients with MM are in high risk of IFI. The lung is the commonest site of infection. The therapeutic effect was similar with itraconazole, voriconazole, caspofungin and amphotericin B liposome in MM patients with complicating IFI. The risk factors for IFI in MM were diabetes, dialysis, persistent agranulocytosis and the use of broad-spectrum antibiotics and fludarabine.

Valdecoxib is a second generation selective COX-2 inhibitor that can induce cell apoptosis in a variety of cell types, but its precise regulatory mechanism is unknown. Apoptosis of Eca109 cells and p38 mRNA expression were investigted. The expression of p-p38MAPK, Fas and FasL proteins were detected by immunohistochemical staining and FCM. Valdecoxib increased the apoptosis rate of Eca109 cells. Fas and FasL protein expression was up-regulated in the valdecoxib groups, while SB203580 partly inhibited the valdecoxib-induced overexpression. Valdecoxib increased p38MAPK expression, while SB203580 inhibited the overexpression of this protein and the apoptosis rate decreased. The expression of Fas, FasL and p38MAPK protein were positively correlated with the apoptotic rate. In conclusion, valdecoxib activates the p38MAPK pathway, thus up-regulating expression of the Fas and FasL proteins, which may be one of the mechanisms through which valdecoxib induces apoptosis.

Background & Objective: Bone marrow angiogenesis plays an important role in the development and prognosis of multiple myeloma (MM). Vascular endothelial growth factor (VEGF) is the most potent stimulatory factor in angiogenesis. This study was to examine the expression of VEGF and its receptors in MM, and analyze their correlations to the tumorigenesis and development of MM., Methods: Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect mRNA expression of VEGF, Flt-1, and KDR in bone marrow samples from 12 newly diagnosed MM patients, 23 relapsed/refractory MM patients, 16 control people, and in KM3 cells., Results: The positive rates of VEGF and Flt-1 were significantly higher in MM patients than in control people (62.9% vs. 18.8%, P<0.01; 80% vs. 31.3%, P<0.01). The mRNA levels of VEGF and Flt-1 were significantly higher in MM patients than in control people (0.41+/-0.19 vs. 0.06+/-0.01, P<0.05; 0.60+/-0.33 vs. 0.08+/-0.03, P<0.01). The positive rates of VEGF and Flt-1 mRNA were not significantly different between newly diagnosed and relapsed/refractory MM patients (66.7% vs. 60.9%, P>0.05; 83.3% vs. 78.3%, P>0.05), and between stage II MM and stage III MM (50% vs. 73.7%, P>0.05; 81.3% vs. 78.9%, P>0.05). The mRNA levels of VEGF and Flt-1 were significantly higher in relapsed/refractory MM patients than in newly diagnosed MM patients (0.49+/-0.20 vs. 0.28+/-0.04, P<0.05; 0.70+/-0.38 vs. 0.41+/-0.06, P<0.05), and were significantly higher in stage III MM than that in stage II MM (0.48+/-0.19 vs. 0.28+/-0.09, P<0.05; 0.75+/-0.35 vs. 0.41+/-0.21, P<0.05). KDR was detected only in 3 MM patients and was not detected in control group., Conclusion: High expression of VEGF and Flt-1 mRNA is associated with the development of MM.

Background & Objective: Cyclooxygenase-2 (COX-2) and signal transducers and activators of transcription (STAT) are closely correlated to the genesis of tumors. This study was to investigate the expression and clinical significance of COX-2, p-Stat3 and p-Stat5 (the activated forms of Stat3 and Stat5) in various lesions of esophageal tissues, and to analyze their correlations to clinicopathologic features of esophageal squamous cell carcinoma (ESCC)., Methods: The expression of COX-2, p-Stat3, and p-Stat5 in 59 specimens of ESCC, 24 specimens of squamous dysplasia, and 18 specimens of normal squamous epithelium was examined by SP immunohistochemistry. Their correlations to clinicopathologic features of ESCC were analyzed., Results: The protein level of COX-2 was significantly higher in ESCC and squamous dysplasia than in normal squamous epithelium (2.10+/-1.77 and 1.85+/-1.24 vs. 0.83+/-0.46, P<0.05). The protein level of p-Stat3 was 0 in normal squamous epithelium, 0.76+/-0.59 in squamous dysplasia, and 2.83+/-1.27 in ESCC. The protein level of p-Stat5 was 1.98+/-0.78 in normal squamous epithelium, 3.92+/-0.41 in squamous dysplasia, and 5.02+/-0.34 in ESCC. There were significant differences among the 3 groups (P<0.05). In ESCC, COX-2 expression was correlated to lymph node metastasis and differentiation (P<0.05); p-Stat3 expression was correlated to tumor invasion depth (P<0.05); but p-Stat5 expression had no correlation to clinicopathologic features. COX-2 expression was positively correlated to both p-Stat3 expression and p-Stat5 expression in ESCC., Conclusions: The up-regulation of COX-2, p-Stat3, and p-Stat5 may be correlated to the carcinogenesis of ESCC. The activation of Stat3 is correlated to the aggressive behavior of ESCC.

Objective: To investigate the effects of ginsenoside Rh2 (GS-Rh2) on growth inhibition and cell cycle of Eca-109 esophageal carcinoma cell line in culture., Method: The effects of GS-Rh2 on cell growth inhibition was detected by MTT assay. Cell cycle was analyzed by flow cytometry (FCM). Cell morphology was observed by a light microscope after HE staining. The protein expression of cell cycle components (cyclinE, CDK2, p21WAF1) were examined by immunocytochemistry and Western blot. The mRNA expression were examined by semiquantitative RT-PCR., Result: GS-Rh2 inhibited the proliferation of Eca-109 cells in dose and time-dependent manners. The inhibition rate was about 50% after 1-day treatment with 20 microg x mL(-1) GS-Rh2 x 20 microg x mL(-1) GS-Rh2 induced the mature differentiation and morphological reversion. With increasing dose of GS-Rh2 treatment, the cell number of G0/G1 phase was increased, whereas it decreased at S and G2/M phase. There was significant difference between 10, 20 microg x mL(-1) GS-Rh2 groups and the corresponding group without GS-Rh2 treatement. After treating cells by 20 microg x mL(-1) GS-Rh2 for 1, 2, 3 days individually, the protein and mRNA expression of both cyclinE and CDK2 reduced, while the expression of p21WAF1 enhanced gradually., Conclusion: GS-Rh2 could arrest Eca-109 cells at G0/G1 phase and induce cell differentiation tending to normal. Furthermore, GS-Rh2 had an effect on expression of cell cycle components (cyclinE, CDK2 and p21WAF1) to inhibit Eca-109 cell proliferation.

Background & Objective: Epstein-Barr virus (EBV) is associated with genesis of many human tumors, including non-Hodgkin's lymphoma (NHL). Latent membrane protein 1 (LMP1) gene is considered as an oncogene of EBV. Recent researches have suggested that LMP1 polymorphisms, especially C-terminal 30bp-deletion (del-LMP1), might be associated with carcinogenicity of EBV, and play important roles in tumorigenesis. This study was to detect expression of del-LMP1 gene in NHL patients and healthy people, and explore relationship of del-LMP1 gene to tumorigenesis and prognosis of NHL., Methods: LMPl gene segments (including the 30 bp deletion) in 48 NHL patients and 60 healthy people were amplified by polymerase chain reaction (PCR) with sequence-specific primers. PCR products were randomly chosen,and sequenced to confirm their specificities and to detect other mutations of LMP1 gene. The distributions of del-LMPl in NHL patients and healthy people were compared. Relationship of del-LMP1 gene to prognosis of NHL was analyzed., Results: (1) LMP1 gene was detected in 23 of 48 NHL patients, 18 of 23 (78%) harbored del-LMPl; LMP1 gene was detected in 32 of 60 healthy people, 13 of 32 (41%) harbored del-LMPl. Positive rate of del-LMPl gene in NHL patients was significantly higher than that in healthy people (P < 0.05). (2) Among 23 EBV-related NHL patients, 15 belonged to high risk group (IPI>/=3), and del-LMPl was detected in 14 of them (93%); 8 belonged to low risk group (IPI<3), and del-LMPl was detected in 4 of them (50%). Positive rate of del-LMP1 in IPI>/=3 group was significantly higher than that in IPI < 3 group (P<0.05). (3)Sequencing confirmed that the 30 bp-deletion located at 168 285-168 256 nt (355-346 aa), and most C-terminal mutations located at 168 357-168 225 nt., Conclusion: Del-LMPl gene exists commonly in EBV-related NHL, and might correlate with prognosis of NHL.